Abstract:IntroductionHydroxychloroquine (HCQ), 4-aminoquinoline, is an antimalarial drug and has become a basic therapy for rheumatic disease treatment. It can stabilize the condition of SLE patients and reduce the chances of patient relapse through its immunosuppressive function and antiinflammatory effects. This drug was absorbed completely and rapidly by oral administration, but has a prolonged half-life for elimination. The objective of this study was to evaluate the pharmacokinetic parameters and relative bioequivalence of a new generic (test) formulation with the branded (reference) formulation of HCQ in healthy Chinese male volunteers. This study was designed to acquire regulatory approval for the test formulation.MethodsThis study was conducted with a randomized, single-dose, two-period, and crossover design. The male subjects were randomly assigned to two groups at a 1:1 ratio to receive 0.2 g hydroxychloroquine sulfate tablets (0.1 g/piece) of the two formulations after a 3-month washout period then administered the alternate formulation. Study drugs were administered after overnight fasting (over 10 h). Plasma concentrations of hydroxychloroquine were measured by a validated LC-MS/MS method. The following pharmacokinetic properties were determined by a noncompartmental pharmacokinetic method: Cmax, Tmax, AUC0–t, AUC0–∝, and t1/2. The bioequivalence between the test and reference products was assessed based on the following parameters: Cmax, AUC0–60d, and AUC0–∝ using the ANOVA method. If the 90% CI for AUC0–t was within 80–125% and for Cmax was within 70–143% of the statistical interval proposed by the SFDA, the two formulations were assumed bioequivalent. Concerning the main pharmacokinetic charateristics of hydroxychloroquine, a long half-life drug, the pharmacokinetic parameters of 0–72 h were determined according to the FDA. Furthermore, a comparison was made between the parameters at 0–60 days and 0–72 h to evaluate whether a truncated AUC method can be applied to estimate the relative bioavailability of HCQ. Tolerability was assessed by monitoring vital signs and laboratory tests and by questioning subjects about adverse events.ResultsThe 90% CI of Cmax for HCQ is 103.8–142.3%; the AUC0–60 is 100–114.2% and AUC0–∝ 100–115.5%. Both met the criteria according to the SFDA’s guidelines for bioequivalence. The relative bioavailability was 109.5% (according to AUC0–60d) and 110.7% (according to AUC0–∝). No serious or unexpected adverse events were observed.ConclusionsIn this study, the pharmacokinetic studies and results were conducted so that the test and reference formulations of HCQ met the Chinese criteria for assuming bioequivalence. Both formulations were well tolerated in the population studies.

An HPLC Method for the Determination of Hydroxychloroquine in Both Serum and Blood Samples and Its Application in SLE Patients

A Sensitive and Optimized HPLC-FLD Method for the Simultaneous Quantification of Hydroxychloroquine and Its Two Metabolites in Blood of Systemic Lupus Erythematosus Patients

A simple and efficient derivatization strategy combined with switchable solvent liquid-liquid microextraction-hydroxychloroquine methyl acetate-d3 based quadruple isotope dilution-gas chromatography-mass spectrometry for the determination of hydroxychloroquine sulfate in biological fluids.

The Blood Concentration of Hydroxychloroquine and Its Safety in Patients with Systemic Lupus Erythematosus

Analysis of Factors Influencing Whole Blood Hydroxychloroquine Concentration in Patients with Systemic Lupus Erythematosus in China.

A HPLC Method for the Separation and Quantification of the Enantiomers of Hydroxychloroquine and Its Three Major Metabolites

Pharmacokinetics and Bioequivalence Study of Hydroxychloroquine Sulfate Tablets in Chinese Healthy Volunteers by LC–MS/MS

HPLC Determination of Low Concentration of Pseudoephedrine Hydrochloride in Human Serum

Application of a multivariate optimization strategy to validate an RP-HPLC analytical method for determining hydroxychloroquine sulphate in pharmaceutical products and in forced degradation studies

Determination of sulphasalazine and its main metabolite sulphapyridine and 5-aminosalicylic acid in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study.

Development of a chiral HPLC method for the separation and quantification of hydroxychloroquine enantiomers

A Novel RP-HPLC-DAD Method Development for Anti-Malarial and COVID-19 Hydroxy Chloroquine Sulfate Tablets and Profiling of In-Vitro Dissolution in Multimedia.

Determination of Related Substances of Chloroquine Phosphate by HPLC

Determination of hydrochloric penehyclidine in human plasma and urine by HPLC-MS / MS

Determination of hydrochlorothiazide in human plasma by liquid chromatography/tandem mass spectrometry.

HPLC Determination of Pseudo-ephedrine Hydrochloride Concentration in Human Plasma

Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of lisinopril in human plasma.

Simultaneous Determination of Malaridine, Sulfadoxine and Pyrimethamine in an Antimalarial Compound Preparation by HPLC

Effect of hydroxychloroquine blood concentration on the efficacy and ocular toxicity of systemic lupus erythematosus

Determination of phenazopyridine hydrochloride in human plasma by LC-MS/MS

RP-HPLC Determination of Chloroprocaine Concentration in Plasma